Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

R406 (free base)

R406 free base is an orally available and competitive Syk/FLT3 inhibitor for ATP binding with a Ki of 30 nM, potently inhibits Syk kinase activity in vitro with an IC50 of 41 nM, measured at an ATP concentration corresponding to its Km value. R406 free base reduces immune complex-mediated inflammation[1]. R406 free base also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM) [2].

Product Specifications

CAS Number

[841290-80-0]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; FLT3; Syk

Type

Reference compound

Related Pathways

Apoptosis; Protein Tyrosine Kinase/RTK

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/R406-free-base.html

Purity

99.07

Solubility

DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

COC1=CC(NC2=NC(NC3=NC(N4)=C(C=C3)OC(C)(C)C4=O)=C(C=N2)F)=CC(OC)=C1OC

Molecular Formula

C22H23FN6O5

Molecular Weight

470.45

Precautions

H302, H315, H319, H335

References & Citations

[1]Sylvia Braselmann, et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther. 2006 Dec;319 (3) :998-1008.|[2]Hoon-Suk Cha , et al. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J Pharmacol Exp Ther. 2006 May;317 (2) :571-8.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Citation 01

Adv Mater. 2024 Mar 15:e2311283.|Harvard Medical School LINCS LIBRARY|iScience. 2024 Jan 11;27 (2) :108869.|Mater Today Bio. 2024 Mar 22:26:101037.|Nature. 2025 Nov 26.|Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|SSRN. 2023 Jun 29.|ACS Infect Dis. 2021 Mar 12;7 (3) :661-671.|Ann Transl Med. 2019 Dec;7 (23) :758.|Arthritis Rheumatol. 2018 Sep;70 (9) :1419-1428. |Atherosclerosis. 2019 Oct;289:132-142.|bioRxiv. 2022 Dec 21, 519945.|bioRxiv. 2024 Apr 9.|Blood Adv. 2024 Nov 12;8 (21) :5653-5662.|BMC Cardiovasc Disord. 2024 Jul 12;24 (1) :354.|Cell Commun Signal. 2024 Apr 2;22 (1) :210.|Cell Death Dis. 2025 Aug 7;16 (1) :595.|Cell Rep Med. 2025 Jan 16:101922.|Cell Rep. 2023 Mar 20;42 (3) :112275.|Cell. 2018 Oct 4;175 (2) :442-457.e23.|Exp Hematol Oncol. 2022 Nov 8;11 (1) :88.|Front Pharmacol. 2022 May 5;13:885053.|iScience. 2024 Jun 28;27 (7) :110415.|iScience. 2024 Mar 27;27 (4) :109607.|J Biol Chem. 2018 Apr 27;293 (17) :6410-6433.|J Neuroinflammation. 2024 Dec 3;21 (1) :318.|J Pharmacol Sci. 2017 May;134 (1) :29-36.|Life Metab. 2025 Jan 29;4 (2) :loaf002.|Mol Immunol. 2024 Jul 31:173:88-98.|Nat Commun. 2022 Apr 19;13 (1) :2136.|Nihon University. School of Medicine. 2014 Mar.|Redox Biol. 2022 Oct:56:102461.|Scand J Immunol. 2024 Apr 26:e13371.|Stony Brook University. 2025.|Theranostics. 2021 May 24;11 (15) :7308-7321.

Available Sizes

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

PE Rat IgG2b, κ Isotype Ctrl
GT17220 100 µg

PE Rat IgG2b, κ Isotype Ctrl

Ask
View Details
Fosmanogepix
JH919289 1 Each

Fosmanogepix

Ask
View Details
Rat CNN3 siRNA
abx912259-01 15 nmol

Rat CNN3 siRNA

Ask
View Details
Rat CNN3 siRNA
abx912259-02 30 nmol

Rat CNN3 siRNA

Ask
View Details